Loading…
Cancer-focused genetic and molecular testing laboratory serving oncologists, hospitals and pharmaceutical companies.
Cancer-focused genetic and molecular testing laboratory serving oncologists, hospitals and pharmaceutical companies.
Clinical testing carries it: labs analyse tumour samples sent by pathologists and oncologists, and it bills the patient's insurer or Medicare for each test, so payer coverage and rates matter. A smaller pharma-services arm runs lab work for drug trials under contract. It bought Inivata in 2021 to add blood-based tests for detecting residual disease.
Moat: narrow (scale, data). One of the largest independent cancer-testing labs, with broad test menu and pharma trial-services relationships.
Headquarters: Fort Myers, Florida · Founded: 2001 · Employees: 2,500
Size NeoGenomics (NEO) is a United States Health Care company (Medical/Nursing Services) with a market value of $2.18B, the 1737th largest of 3,117 United States companies the cockpit tracks. Shares closed at $16.84 on 6 Nov 2026.
Performance Over six months the shares gained 88.0%, against +24.9% for the median peer and -1.1% for the United States market (cap-weighted) — 5th highest of 20 in its peer set.
Growth Revenue grew 11.1% over the last twelve months (peer median +5.9%); the operating margin is -5.9% (peer median 8.0%).
Valuation It trades at 58.9× forward earnings against a peer median of 40.1× (6th most expensive of 16).
Capital Return on invested capital runs 16.0 points below its cost of capital (12.7% WACC).
Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $788M | $727M | $661M | $592M | $510M |
| Revenue growth | — | +10% | +12% | +16% | — |
| Gross profit | $336M | $283M | $257M | $209M | $173M |
| EBITDA | $18.8M | $1.75M | $852,000 | -$24.1M | -$71.4M |
| Net income | -$32.3M | -$108M | -$78.7M | -$88.0M | -$144M |
| Free cash flow | -$28.6M | -$21.8M | -$34.0M | -$30.7M | -$96.9M |
| Capital expenditure | $32.9M | $27.0M | $41.1M | $28.8M | $30.9M |
| Total debt | $449M | $409M | $605M | $612M | $611M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| NeoGenomics NEO | $2.18B | +88% | +11% | -6% | 58.9× | n/a |
| Labcorp LH | $29.8B | +45% | +6% | 11% | 19.0× | 13.9% |
| Quest Diagnostics DGX | $28.1B | +36% | +9% | 15% | 22.0× | 6.4% |
| Guardant Health GH | $20.2B | +58% | +43% | -40% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NEO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.1% | +8.6% | 7th lowest of 21 |
| 6-month return | +88.0% | +24.9% | 5th highest of 20 |
| Distance from 52-week high | -16.4% | -15.2% | 9th lowest of 21 |
| Revenue growth (TTM) | +11.1% | +5.9% | 10th highest of 21 |
| Operating margin | -5.9% | 8.0% | 4th lowest of 21 |
| Forward P/E | 58.9× | 40.1× | 6th most expensive of 16 |
| ROIC minus cost of capital | -16.0 pp | -1.1 pp | 4th lowest of 20 |
| Net debt / EBITDA | 16.5× | 1.0× | 2nd most indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| NeoGenomics NEO | United States | $2.18B | +88% | +11% | -6% | 58.9× | n/a | n/a |
| AddLife ALIF-B.ST | Sweden | $2.29B | +25% | +2% | 8% | 40.5× | 21.6% | +14.6% |
| Addus HomeCare ADUS | United States | $2.32B | +25% | +12% | 11% | 16.6× | 4.9% | +13.2% |
| Guangzhou Kingmed Diagnostics 603882.SS | China | $1.99B | +5% | -3% | 7% | 31.7× | 6.7% | -6.1% |
| Dian Diagnostics 300244.SZ | China | $1.97B | +11% | -5% | 9% | 25.2× | 2.4% | -1.1% |
| Emeis EMEIS.PA | France | $1.94B | -30% | +4% | 3% | n/a | 21.3% | +8.5% |
| Pediatrix Medical MD | United States | $2.44B | +33% | +2% | 12% | 12.9× | -4.5% | +2.0% |
| agilon health AGL | United States | $1.90B | +109% | 0% | -4% | 67.5× | n/a | n/a |
| GeneDx WGS | United States | $1.86B | +53% | +25% | -12% | 98.7× | n/a | n/a |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.74B | +15% | +22% | 15% | 89.1× | 41.9% | +26.9% |
| Azenta AZTA | United States | $1.72B | +104% | +1% | -3% | 103.7× | 56.0% | +8.9% |
| Personalis PSNL | United States | $1.71B | +164% | -13% | -164% | n/a | n/a | n/a |
| Aveanna Healthcare AVAH | United States | $2.89B | +97% | +20% | 11% | 15.4× | 13.4% | +10.2% |
| Meinian Onehealth Healthcare 002044.SZ | China | $2.89B | -9% | -4% | 9% | 55.1× | 5.8% | +5.7% |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.63B | -47% | +8% | 3% | 40.1× | 15.0% | -5.1% |
| Ambea AMBEA.ST | Sweden | $1.63B | +30% | +13% | 8% | 15.8× | 1.7% | +7.7% |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.60B | +22% | +24% | 32% | 64.3× | 39.3% | +16.7% |
| Teladoc Health TDOC | United States | $1.60B | +21% | -2% | -5% | n/a | -5.2% | +18.3% |
| Sonida Senior Living SNDA | United States | $1.58B | -14% | +49% | -11% | n/a | n/a | n/a |
| Fameglow 3774.HK | Hong Kong | $3.19B | n/a | +36% | 11% | n/a | 48.8% | +48.4% |
| U.S. Physical Therapy USPH | United States | $1.48B | +68% | +11% | 10% | 30.4× | 19.9% | +13.0% |